Evidence map›Paper›PMID 30158840›Full record

Trial reportTheScientificWorldJournal2018

A Pilot Study of Short-Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patients with Diabetic Foot Ulcer Wagner 3-4.

Hendry Irawan, I Nyoman Semadi, I Gde Raka Widiana

2 registry-linked trialsOpen access · goldAbstract readClinical Trial
In one paragraph

Trial report in TheScientificWorldJournal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 2 registered trials, which are not on this map. Cited by 9 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed, 2 pooled it
2.0field-weighted citation impact, top 13% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT03615755 nacompletednot on this map

A Pilot Study of Short Duration Hyperbaric Oxygen Therapy to Improve HbA1c, Leukocyte, and Serum Creatinine in Patient With Diabetic Foot Ulcer Wagner 3-4

TypeinterventionalSponsorHendry IrawanRan2016 to 2017Enrolled30ConditionsHyperbaric Oxygen Therapy, Diabetic Foot Ulcer, Type II Diabetes MellitusArmsHyperbaric Oxygen Therapy (HBOT)
NCT03939000 completednot on this map

Clinical Profile and Laboratory Finding of Diabetic Foot Ulcers From Tertiary Hospitals in Bali

TypeobservationalSponsorUdayana UniversityRan2016 to 2019Enrolled113ConditionsDiabetic Foot Ulcer, Type 2 Diabetes Mellitus, Laboratory Problem, Physical Findings.Skin Ulcer
3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 2 syntheses or guidelines pooled it, 23 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. HPharmaceutics · 2023
    Article
  5. Review
  6. Article
  7. Diabetic Wound-Healing Science.Medicina (Kaunas, Lithuania) · 2021
    Review
  8. Article
  9. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Hendry IrawanSurgery Department, Faculty of Medicine, Udayana University, Sanglah General Hospital, Denpasar, Indonesia.ORCID 0000-0003-1000-1691
I Nyoman SemadiThorax and Cardiovascular Surgery Division, Surgery Department, Faculty of Medicine, Udayana University, Sanglah General Hospital, Denpasar, Indonesia.
I Gde Raka WidianaNephrology and Hypertension Division, Internal Medicine Department, Faculty of Medicine, Udayana University, Sanglah General Hospital, Denpasar, Indonesia.
Udayana University · ID

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

objectiveTo evaluate the short-duration hyperbaric oxygen therapy (HBOT) can improve HbA1c levels, leukocyte count, and serum creatinine levels in patients with diabetic foot ulcer (DFU) Wagner 3-4.

methodsBlood samples from all DFU patients at Sanglah General Hospital, Denpasar, were taken for HbA1c, leukocyte, and serum creatinine test before debridement procedure, and the patients were then grouped into either standard therapy or standard therapy with HBOT for 10 sessions (combination therapy). At the end of therapy, all blood tests were resumed.

resultsEach group consisted of 15 patients. Results of laboratory analysis before and after treatment were significant regarding decrease of HbA1c levels in standard therapy (10.98 ± 2.37 % to 9.70 ± 2.46 %; p = 0.006), HbA1c levels in combination therapy (9.42 ± 1.96 % to 7.07 ± 1.16 %; p < 0.001), and leukocyte count in combination therapy (13.97 ± 6.24 x 10

conclusionThe use of short-duration HBOT on DFU reduces HbA1c levels, leukocyte count, and serum creatinine levels better than standard therapy alone. This protocol would save time and effort in future HBOT implementation. This trial is registered with ClinicalTrials.gov Identifier: NCT03615755.

Indexed as

AdultBiomarkersCreatinineDiabetic FootFemaleGlycated HemoglobinHumansHyperbaric OxygenationLeukocytesMaleMiddle AgedPilot ProjectsTime FactorsWound HealingBiomarkersCreatinineGlycated Hemoglobinhemoglobin A1c protein, human

Identifiers

PMID30158840
PMCPMC6109474
OpenAlexW2885262111

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.